KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanomaPier Francesco Ferrucci, Paolo A. Ascierto, Anna Maria Di Giacomo et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 178
P3.13C.02 A Plasma Proteomics-Based Model for Clinical Benefit Prediction in Small Cell Lung Cancer Patients Receiving ImmunotherapyDavid R. Gandara, M.A. Schneider, Igor Puzanov et al.|Journal of Thoracic Oncology|2024Cited by 0